Ascendis Pharma A/S (NASDAQ:ASND) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a report published on Saturday.

A number of other analysts have also recently commented on ASND. Wells Fargo & Company restated an “overweight” rating and issued a $295.00 price objective (up from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Wedbush boosted their price objective on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Cantor Fitzgerald boosted their price objective on Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Moderate Buy” and a consensus target price of $249.80.

Ascendis Pharma A/S Trading Up 1.7%

Shares of ASND stock opened at $210.50 on Friday. The stock has a 50 day moving average of $199.16 and a 200 day moving average of $177.64. The stock has a market cap of $12.99 billion, a P/E ratio of -40.79 and a beta of 0.41. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in Ascendis Pharma A/S by 1.7% during the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after buying an additional 168,752 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Ascendis Pharma A/S by 12.0% during the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after buying an additional 328,278 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Ascendis Pharma A/S by 1.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,901,843 shares of the biotechnology company’s stock worth $328,258,000 after buying an additional 23,926 shares during the last quarter. Invesco Ltd. boosted its stake in Ascendis Pharma A/S by 3.7% during the first quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company’s stock worth $186,795,000 after buying an additional 42,465 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Ascendis Pharma A/S during the second quarter worth $166,367,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.